AI
ADMS

Axiom Investors’s Adamas Pharmaceuticals ADMS Stock Holding History

Axiom Investors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-74,910
Closed -$1.79M – 166
2018
Q1 		$1.79M Sell
74,910
-7,270
-9% -$229K 0.04% 126
2017
Q4 		$2.79M Sell
82,180
-154,029
-65% -$4.3M 0.07% 106
2017
Q3 		$5M Buy
236,209
+135,297
+134% +$2.48M 0.11% 90
2017
Q2 		$1.76M Buy
+100,912
New +$1.67M 0.04% 123

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Axiom Investors's ADMS Position: Q2 2018 in Review

Axiom Investors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 74,910 shares — an estimated $1.79M sold.

Axiom Investors first reported a position in ADMS in Q2 2017 and held it in 4 quarters. The position peaked at $5M in Q3 2017. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

  • Axiom Investors reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Axiom Investors sold 74,910 Adamas Pharmaceuticals shares in Q2 2018, an estimated $1.79M.
  • Axiom Investors first reported a position in Adamas Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Axiom Investors's Adamas Pharmaceuticals position peaked at $5M in Q3 2017.
  • 126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Axiom Investors's 13F filing for Q2 2018, filed 13 Aug 2018.